Format

Send to

Choose Destination
J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S58-71. doi: 10.1016/j.jacl.2014.03.004.

An assessment by the Statin Muscle Safety Task Force: 2014 update.

Author information

1
Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA. Electronic address: robert.rosenson@mssm.edu.
2
McMaster University, Hamilton, ON, Canada.
3
Emory University, Atlanta, GA, USA.
4
Mayo Clinic, Rochester, MN, USA.
5
Department of Cardiology, Henry Low Heart Center, Hartford Hospital, Hartford, CT, USA.

Abstract

The National Lipid Association's Muscle Safety Expert Panel was charged with the duty of examining the definitions for statin-associated muscle adverse events, development of a clinical index to assess myalgia, and the use of diagnostic neuromuscular studies to investigate muscle adverse events. We provide guidance as to when a patient should be considered for referral to neuromuscular specialists and indications for the performance of a skeletal muscle biopsy. Based on this review of evidence, we developed an algorithm for the evaluation and treatment of patients who may be intolerant to statins as the result of adverse muscle events. The panel was composed of clinical cardiologists, clinical lipidologists, an exercise physiologist, and a neuromuscular specialist.

KEYWORDS:

Muscle adverse events; Myalgia; Myopathy; Neuromuscular testing; Rhabdomyolysis; Statin intolerance; Statins

PMID:
24793443
DOI:
10.1016/j.jacl.2014.03.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center